Abstract | Axon degeneration is a prominent early feature of most neurodegenerative disorders and can also be induced directly by nerve injury in a process known as Wallerian degeneration. The discovery of genetic mutations that delay Wallerian degeneration has provided insight into mechanisms underlying axon degeneration in disease. Rapid Wallerian degeneration requires the pro-degenerative molecules SARM1 and PHR1. Nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) is essential for axon growth and survival. Its loss from injured axons may activate Wallerian degeneration, whereas NMNAT overexpression rescues axons from degeneration. Here, we discuss the roles of these and other proposed regulators of Wallerian degeneration, new opportunities for understanding disease mechanisms and intriguing links between Wallerian degeneration, innate immunity, synaptic growth and cell death.
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exacerbates the effects of agerelated disorders. Thus, it is essential to understand and devise means to target the mechanisms underlying axon degeneration.
The capacity of experimental models of these dis eases to shed light on the mechanisms of axonal loss is often limited because the onset of degeneration is both gradual and heterogeneous within an axonal popula tion and because where and how pathogenesis begins is uncertain. By contrast, Wallerian degeneration is a pro cess in which axonal injury at a defined site and time simultaneously affects all axons (FIG. 1) . These features have enabled considerable progress to be made towards understanding the mechanisms underlying Wallerian degeneration.
During Wallerian degeneration, the distal portions of injured axons fragment after a predictable latent phase, which lasts 36-44 hours in the mouse sciatic nerve 2 . Several genetic mutations delay Wallerian axon degen eration for 10 days or more [3] [4] [5] . For example, nicotinamide mononucleotide adenylyltransferases (NMNATs)
, including the slow Wallerian degeneration protein (WLD S ), which contains NMNAT1 (FIG. 2) , delay Wallerian degeneration up to tenfold when overexpressed within axons 3, [6] [7] [8] [9] . For several years, most research in this field focused on these mutations, which conferred a gain of function; however, new studies using mutations that result in a loss of function have begun to ask how Wallerian degeneration is initiated and which proteins are required for its completion. For example, the removal of one endogenous NMNAT isoform that is present in axons, NMNAT2 (FIG. 3) , causes WLD S sensitive axon degenera tion [10] [11] [12] . Conversely, deletion of SARM1 delays Wallerian degeneration to the same extent as WLD S , suggesting that it has a function in axon death signalling 4 . Loss of PHR1 (also known as MYCBP2) has a protective effect in vivo that approaches the same level as that of SARM1 and WLD S (REF. 5). Current evidence suggests that a range of other modifiers influence Wallerian degeneration more modestly (although in some cases, their full efficacy in vivo remains to be established). The in vivo effects of NMNATs, SARM1 and PHR1 are closely reproduced both in primary cultures of mammalian neurons and by their Drosophila melanogaster orthologues dNmnat, dSarm and Highwire, respectively 4, [13] [14] [15] . This has facilitated studies of the exogenous agents and genetic manipulations that influence Wallerian degeneration.
Axonal arbors
The terminal regions of axons exhibiting a variable degree of branching. Extreme cases such as nigrostriatal dopaminergic neurons have tens of thousands of branches.
Nicotinamide mononucleotide adenylyltransferases
(NMNATs). Enzymes that catalyse the final step in NAD + synthesis, on which all the NAD + biosynthetic pathways converge.
Wallerian degeneration: an emerging axon death pathway linking injury and disease Nature Reviews | Neuroscience 
c Wallerian degeneration
Known lesion with precise site and timing Mixed nerve: sensory and motor axons, myelinated and unmyelinated axons All axons degenerate after injury with broadly similar timing Thus, experimental Wallerian degeneration is an excellent model system that can be used to understand one pathway of axon degeneration. Testing whether disease models are influenced by these mutations can then enable us to relate this mechanism back to those taking place in neurodegenerative diseases. Many dif ferent types of stress initiate axon loss. For example, inflammatory damage mediates multiple sclerosis, per turbations of mRNA metabolism are implicated in sev eral types of motor neuron disease, poor mitochondrial quality control may be important in some Parkinson's disease cases and failure of glial support or disrup tions of axonal transport are causative factors in some peripheral neuropathies 16 . Despite this diversity of causes, there is evidence of some convergence onto a common pathway. Overexpression of WLD S delays axon degeneration in some peripheral neuropathy, Parkinson's disease and motor neuron disease mod els, suggesting that there is at least one shared step in the axon degeneration pathways in these disorders [17] [18] [19] [20] [21] . Even in models that are not influenced by WLD S , such as some transgenic ALS models featuring superoxide dismutase 1 (SOD1) mutations 22 , this approach helps to categorize degenerative mechanisms (TABLE 1) .
In this article, we review recent studies that have increased our understanding of the relationship between Wallerian degeneration and axon loss in disease and the opportunities for studies using newly identified regula tors to extend this knowledge. We begin by discussing progress towards a full understanding of the Wallerian degeneration pathway. Determining the order in which events occur in this pathway and defining the putative initiation and execution phases are key aims to help to identify the best steps to target therapeutically. Finally, we ask whether the roles of SARM1 in innate immunity and cell death, and of PHR1 in synaptic growth, indicate mechanistic overlap between Wallerian degeneration and other important biological processes. WLD S -sensitive degeneration Injuryinduced axon degeneration, now known as Wallerian degeneration, was first described in 1850 by Augustus Waller, who predicted "important … appli cations … in relation to nervous diseases" (REF. 23 ). The term 'Wallerianlike degeneration' traditionally describes axon degeneration that is morphologically similar to that occurring after injury, such as that seen in peripheral neuropathies, ALS and other disorders. Wallerianlike degeneration features include granular disintegration of the cytoskeleton, the presence of ovoids of degenerating myelin, fragmentation of distal axons and, in the CNS, large axonal swellings. Morphological similarity does not necessarily imply a related molecu lar mechanism, but the serendipitous discovery of the spontaneous mutant Wld S mouse 24 , 139 years after Waller described injuryinduced axon degeneration, finally made it possible to confirm that axon loss in some disease models is mechanistically related to Wallerian degeneration 17, 20, 25, 26 (TABLE 1) . WLD S protects axons after injury and in some (but not all) models that fit the clas sical definition of Wallerianlike degeneration. Thus, in Figure 1 | Systems for studying axon degeneration. A schematic representation of the causes and features of axon degeneration in different diseases and model systems. a,b | Early loss of axons is common in neurodegenerative disorders, but the mechanisms can be difficult to study directly in disease models. In amyotrophic lateral sclerosis, for example, several different causative factors have been proposed to lead to axonal degeneration in a population of vulnerable spinal motor neurons. This leads to disruption of the connectivity between the muscles and spinal cord and, eventually, to the death of the affected neurons. A population of 'resistant' motor axons, however, do not undergo degeneration in response to these stressors. Similarly, in Alzheimer's disease, the effects of amyloid-β (Aβ) peptide, tau pathology and a combination of other causative factors result in axonal dystrophy in vulnerable neurons. Other axons may encounter less of these pathogenic factors and do not degenerate. Progress towards understanding mechanisms of axon degeneration in these disorders is therefore limited by their multifactorial causes, by heterogeneity in the timing and sites of key pathogenic events and by the differential responses of vulnerable or resistant axons. c | By contrast, in Wallerian degeneration (injury-induced axon degeneration), the location and timing of the initial lesion is well understood and the process involves sudden degeneration of all axons in a nerve within a short time window after nerve injury 2 . Consequently, progress towards understanding this mechanism can be made relatively quickly. APOE, apolipoprotein E; DRG, dorsal root ganglion; ER, endoplasmic reticulum.
Axonal transport
The bidirectional trafficking of molecules and organelles along axons. Long-range transport is mediated by the progression of kinesin (anterograde) and dynein (retrograde) motor proteins along microtubules.
this Review, we use the term 'WLD S sensitive degenera tion' to refer to conditions in which WLD S (or related NMNAT enzymes) delays the degenerative process.
Towards a Wallerian degeneration pathway As described above, injured axons in Wld S mice show prolonged survival. This finding challenged the ear lier assumption that axon degeneration is a passive consequence of separation from cell bodies and sug gested that Wallerian degeneration and other types of WLD S sensitive axon degeneration are active processes that involve an autonomous selfdestruction pathway.
Although Wallerian degeneration seems to be largely distinct from apoptosis in molecular terms [27] [28] [29] , there are some clear parallels. Both are conserved processes
, each with a latent phase during which initiating events occur without morphological change, and an execution phase involving frank breakdown of the cell or axon. Apoptosis also features a particular stage after which a cell is committed to die but before which cell death can be prevented by removing the triggering insult 30 . Axon transection is irreversible, but there is evidence from a nontransecting, reversible model that WLD S sensitive degeneration can also be prevented before a commitment point is reached. The degeneration of uninjured superior cervical ganglion (SCG) neurites that occurs after protein synthesis is blocked using the reversible translation inhibi tor cycloheximide is only slightly slower than the degen eration that occurs after injury and is strongly delayed by WLD S (REF. 10). However, even wildtype neurites remain healthy if cycloheximide is removed within 4-6 hours of its addition, whereas later removal from overtly healthy cultures fails to prevent their subsequent degeneration.
The number of known modulators of Wallerian degen eration has grown considerably over the past few years, but attempts to integrate these into a cohesive pathway have been limited. Determining the sequence of events is crucial for understanding related disease mechanisms and for identifying the most appropriate targets for therapeutic manipulation. Here, we propose that these events can be ordered into a conserved signalling pathway, consisting of initiation and execution phases, that is triggered by injury or other stresses (FIG. 4) . We hypothesize that a series of core events receive various modifying inputs and we have putatively assigned molecules to these different groups based on the type and relative strength of reported phe notypes. Specifically, molecules involved in core events are defined here as those for which a gain or loss of function either confers protection against Wallerian degeneration that is comparable with the archetypical tenfold delay provided by WLD S expression or induces WLD S sensitive degeneration of otherwise undamaged axons. Core events would thus include those that are influenced by WLD S , SARM1 and PHR1. Modifiers of the pathway are defined as those that have more modest but significant effects. In some cases, the full phenotype of a gain or loss of func tion of the proposed pathway modifier has not yet been tested in vivo, so future data may suggest that they are core components. Thus, our categorizations and relative positioning of different events should not be considered definitive; rather, we hope that they will act as a stimulus for future studies.
The initiation phase
The question of whether Wallerian degeneration is initi ated by the absence of a survival signal from cell bodies or by a prodegenerative signal originating from the injury site has long been discussed 31 . (FIG. 3a) . In addition to its action as a co-enzyme involved in redox reactions, NAD + has key signalling roles: it mobilizes calcium through its metabolites ADP ribose (ADPR), cyclic ADPR and nicotinic acid adenine dinucleotide phosphate (NAADP), and contributes to post-translational protein modifications such as deacetylation, which is catalysed by sirtuins, and mono-or poly-ADP ribosylation, which is catalysed by mono(ADP ribose) transferases (ARTs) and poly(ADP ribose) polymerases (PARPs).
Compartmentalization of NMNAT isoenzymes NMNAT enzymes are found in all organisms. The three mammalian isoforms differ in enzymatic properties, tissue distribution and subcellular localization 141 : NMNAT1 is localized to the nucleus and widely expressed; NMNAT2 is found in the cytoplasm and axoplasm and is abundant in the brain; and NMNAT3 is probably localized to mitochondria (although this has been questioned 88 ) and is weakly expressed in the brain. Similarly, NAD + -consuming enzymes, and hence probably NAD + metabolic pools, are also compartmentalized 141 (FIG. 3b) .
This compartmentalization is particularly evident in neurons, in which distal axons may be separated by long distances from cell bodies. NMNAT1 provides NAD + as substrate for nuclear enzymes, such as SIRT1 and PARP1, and is essential for neuronal survival in the retina and probably elsewhere [136] [137] [138] [139] . NMNAT2 undergoes fast, bidirectional axonal transport and is essential for axon survival and growth [10] [11] [12] . Mitochondrial NAD + , which may be synthesized by NMNAT3 (REFS 88, 142) , is involved in regulating cellular energy balance through mitochondrial sirtuins and PARPs. The enzyme involved in the preceding step in the NAD + salvage pathway, nicotinamide phosphoribosyltransferase (NAMPT), is homogeneously distributed within neurons 143 , so localized distribution of NMNAT isoforms is the distinguishing feature of compartmentalized NAD + synthesis (FIG. 3) . These isoforms have at least partly non-redundant functions, as deleting either NMNAT1 or NMNAT2 is lethal 12, 86 .
Where does WLD
S act to protect axons? WLD S is predominantly nuclear, reflecting the nuclear localization of NMNAT1 (REF.
3) (FIGS 2,3b). This led to the suggestion that it has a nuclear axon-protective action, which is mediated by SIRT1 (REF. 46 ). However, small amounts of WLD S are also present in axons, and multiple lines of evidence indicate this is the location where WLD S acts to delay injury-induced degeneration 39, 41, 83 . Although a mitochondrial site of action for WLD S has also been discussed 8, 84 , it remains unclear which of the many cytoplasmic fractions containing WLD S is its site of action 8, 83 . WLD S -binding partner valosin-containing protein (VCP) (FIGS 2, 3b) is widely distributed but is most abundant at the surface of cytoplasmic organelles 144 . A highly protective WLD S variant in which nuclear localization is disrupted partially localizes to mitochondria and the endoplasmic reticulum 83 . Other protective constructs, in which NMNAT1 is targeted to axons or the cytoplasm, are distributed among all subcellular and cytosolic compartments 9 or present with a diffuse extranuclear appearance 6 , respectively. Lentivirally transduced NMNAT1 does enter axons 41, 54 , and strongly overexpressed NMNAT3 is observed in the cytosol and cytoplasm in addition to mitochondria 8 . Thus, overexpressed NMNAT1 and NMNAT3 may act in one of these ectopic locations to delay Wallerian degeneration rather than in nuclei or mitochondria. Interestingly, NMNAT2 is axonally transported on Golgi-derived vesicles, but its protective efficacy is greatly increased (to a level comparable with WLD S ) if it is detached from these vesicles 38 . This suggests a non-vesicular site of action for NMNAT enzyme activity. Nature Reviews | Neuroscience 
Apoptosis
An active programme of cell death effected by caspases, a family of cysteine-dependent proteases, and regulated by BCL-2 family proteins.
Chimeric gene
A gene formed by the fusion of two normal genes, which can occur as the result of genomic rearrangement such as an intra-chromosomal duplication or triplication, or an inter-chromosomal translocation. Expression of a fusion protein is one of several possible outcomes.
stresses has shown that an injuryderived signal such as calcium influx through the cut site is not necessary to initiate such a pathway. For example, genetic or toxic disruption of axonal transport, protein synthesis inhibi tion, Nmnat2 knockdown and mutation of Schwann cell proteins all induce WLD S sensitive degeneration without physical injury 10, 20, 32, 33 . NMNATs, PHR1 and Highwire. The robust delay of Wallerian and Wallerianlike axon degeneration conferred by ectopic expression of WLD S , or ectopic overexpression or engineered mislocalization of any of the three mamma lian NMNATs, is highly reproducible both in vivo in var ied organisms and in primary culture 3, 7, 8, 13, [34] [35] [36] . Together with the early depletion of NAD + in injured axons, which is prevented by WLD S (REF. 37), this suggests that loss of a crucial NMNAT function is a core event in the Wallerian degeneration pathway. As several different physical or toxic initiating stresses can trigger WLD S sensitive degen eration, we suggest that these pathways converge on or before this NMNAT step.
Data from our own research and that of others suggest that loss of endogenous NMNAT2 is a good candidate for the putative core NMNATreversible event. NMNAT2 is present in axons and is continuously trafficked by a popu lation of Golgiderived vesicles 10, 38 . Like other endogenous NMNAT isoforms and WLD S , exogenous overexpression of NMNAT2 delays Wallerian degeneration. However, because NMNAT2 is much more labile than the other NMNATs (its halflife is under 1 hour), the wildtype pro tein is protective only when expressed at high levels 10, 38 . In vivo, constitutive genetic depletion of NMNAT2 dur ing development leads to stalled axon outgrowth, which results in axon truncation, failed peripheral innervation and perinatal lethality, consistent with a critical axonal function for this protein 11, 12 . The levels of highly labile NMNAT2 rapidly decline after neurite transection in primary culture before degeneration, which led us to propose that early loss of this essential axon maintenance factor is a critical initiating event for subsequent degen eration 10 . Indeed, in primary culture, small interfering RNAmediated Nmnat2 knockdown is sufficient to initi ate robust axon degeneration that is independent of cell death and not prevented by the presence of other endog enous NMNAT isoforms 10 . Consistent with our model, WLD S rescues the NMNAT2 depletion phenotype both in primary culture and in vivo, probably by directly substitut ing its NMNAT function in axons 10, 11 . In mammalian neu rons, especially in primary culture, the effects of PHR1 depletion on axon survival and NMNAT2 stabilization are significant but somewhat weaker than the effects of Highwire in flies 5 . This may reflect greater complexity in the regulation of NMNAT2 turnover in mammals, perhaps specifically in injured axons, although incom plete Cremediated deletion of PHR1 in the neuronal population may also have contributed. Finally, slow ing the ubiquitylation and turnover of NMNAT2 by disrupting its palmitoylationdependent localization to Golgiderived vesicles strongly increases its protective capacity both in primary culture and in vivo 7, 38 . Together, these studies support the hypothesis that regulation of NMNAT2 turnover or activity could be a crucial, early node in the Wallerian degeneration pathway (FIG. 4) .
Although the 'NMNAT2 depletion model' has not been directly challenged by contradictory data, some important questions remain. Foremost is how this unsta ble protein reaches the ends of longer axons in sufficient quantities to ensure viability. Local protein translation is one possibility. Global suppression of protein synthe sis does not discernibly alter Wallerian degeneration in ) is a chimeric gene that results from a tandem triplication 11 and encodes full-length nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1) (BOX 1) fused to 70 amino-terminal amino acids (N70) from the ubiquitin ligase UBE4B (ubiquitin conjugation factor E4 B). N70 does not contain UBE4B catalytic activity but retains a small motif within the N-terminal 16 amino acids that binds to the ubiquitous cytoplasmic protein valosin-containing protein (VCP; also known as p97). This sequence is important for the localization of WLD S in the cytoplasm and axoplasm 48, 49 A variant WLD S lacking this motif (not shown) shows a predominant nuclear location and fails to confer axon protection 48, 49 . An 18 amino acid-linker sequence (18AA) originates from the 5′ untranslated region of NMNAT1 and is unique to WLD 64, 66, 90 , but this remains to be confirmed for the endogenous protein (see text) and seems to be unnecessary for axon degeneration 64 . The SAM and TIR sequences are both essential for rapid axon degeneration, probably acting as sites for homodimerization and signalling, respectively 64 . The N-terminal ARM domain appears to inhibit the pro-degenerative function, as its removal seems to generate a constitutively active protein 64 . 
Nicotinic acid
, which is naturally present only in Wld S mice, is found in axons but with a much higher concentration in nuclei. Variant forms of WLD S and NMNATs (not shown for reasons of clarity) have also been generated for structure-function studies. Cytoplasmic NMNAT1, axonal NMNAT1 and ΔNLS-WLD S all increased the amount of WLD S or NMNAT1 in axons 6, 9, 83 , and NMNAT2ΔEx6 is a variant form of NMNAT2 with disrupted tethering to Golgi-derived vesicles 7 . Each of these modifications increased the protective activity relative to NMNAT1, WLD S and NMNAT2, respectively. Ataxin (ATX)-WLD S , where the valosin-containing protein (VCP)-binding site is replaced with a motif derived from the protein ATX3, restores the protective capacity of the N-terminally truncated WLD S (REF. 49 ). ER, endoplasmic reticulum; NaAD, nicotinic acid adenine dinucleotide; NADS, NAD + synthase; NaMN, nicotinic acid mononucleotide; NaPRT, nicotinic acid phosphoribosyltransferase; PPi, pyrophosphate; PRPP, phosphoribosyl pyrophosphate.
Axon pruning
The developmentally programmed loss of axon branches, for example, during Drosophila melanogaster metamorphosis and refinement of retinotectal projections. Nerve growth factor withdrawal is used as a culture model of axon pruning, although how closely mechanisms are related is unclear.
FK866
An inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) with an extended binding site at the interface between the two monomers. FK866 greatly lowers NAD + concentration in many cell types, which is why it is used in clinical trials as an anti-cancer drug.
Chaperone
A protein that facilitates the folding or assembly of another protein to prevent misfolding and abnormal aggregation.
Toll-like receptor (TLR). A receptor for pathogenassociated molecular patterns (PAMPs) that signals through its Toll-interleukin-1 receptor (TIR) domain to activate inflammation or cell death. SARM1 is one of five intracellular adaptors for TLR signalling.
injured primary culture neurites 10 , but further investi gation is needed in vivo. Alternatively, distinct pools of NMNAT2 with different halflives may exist. The ability of a cytoplasmic NMNAT1 variant to protect cut dorsal root ganglion (DRG) neurites when virally transduced into the neurites 4 hours after injury 41 (after substantial NMNAT2 loss has occurred 10,38 ) may reflect slow pro gression of downstream events or suggest that there is a second NMNATmodifiable event later in the pathway. This may fit with some alternative models of axon degen eration (see below). Finally, WLD S and a cytoplasmic variant of NMNAT1 confer strong protection against axon degeneration induced by nerve growth factor (NGF) withdrawal 27, 42 ; however, this in vitro model of axon pruning proceeds through activation of a seemingly different path way that culminates in caspase activation [42] [43] [44] [45] . It remains unclear whether NMNAT2 loss is also involved in this pathway or whether NMNAT activity affects another event following NGF withdrawal.
There , and increasing endogenous NAD + in mice by remov ing the NAD + consuming enzymes CD38 and PARP1 (poly(ADP ribose) polymerase 1) confers no protection 50 . Remarkably, pharmacological inhibition of nicotina mide phosphoribosyltransferase (NAMPT), the ratelim iting enzyme in the NAD + salvage pathway
, lowers NAD + levels but confers moderate protection against neurite degeneration induced by injury or energy dep rivation 50, 56 rather than reversing the axon protection by NMNATs as might have been expected. WLD S expression and NAMPT inhibition have both been shown to counter an early decline in ATP levels after energy deprivation, so it has been suggested that NMNATs might catalyse the reverse reaction to produce ATP and NMN from NAD + (REF. 56 ). However, whether ATP loss is a cause or con sequence of injuryinduced axon degeneration remains unclear. Interestingly, stimulation of the NAD + biosyn thetic pathway at multiple points, including NAMPT (sometimes abbreviated to NmPRT) overexpression before axotomy, also seems to have protective effects that are comparable to the effects of NAMPT inhibition by FK866 after axotomy 50, 52 , suggesting that complex interac tions occur between the different steps. Further studies of NAD + related metabolites, particularly NMN (FIG. 3) , should help to resolve these questions.
Intriguingly, enzymatically inactive NMNATs have been reported to delay noninjury and developmen tal axon degeneration in some models through an independent chaperone function, which potentially underlies amelioration of pathology in some models of protein aggregation disorders [57] [58] [59] [60] [61] [62] [63] . It remains to be determined whether axon and synapse loss in these sit uations is mechanistically related to Wallerian degen eration or secondary to the effects of protein aggregates on cell bodies. Establishing which aspect of NMNAT function is important in any particular context will be crucial for devising appropriate therapeutic strategies. Importantly, enzymatic activityindependent neuro protection has so far only been demonstrated using overexpression of enzymedead NMNAT mutants, or using other chaperones, such as Heat shock protein 26 (Hsp26) and Hsp70 (REF. 62 ). It will be important to test whether this alters enzymatic activity or stability of endogenous NMNATs. 
SARM1 and dSarm. An absence of the
. Three nonsense alleles of dSarm, the D. melanogaster orthologue of murine Sarm1, conferred robust axon protection, and SARM1 was shown to be required for rapid Wallerian degeneration in mice 4 . Like Wld S axons, Sarm1 −/− axons survive for over 2 weeks after nerve injury, and this strik ing protective effect is replicated in primary culture 4 , which shows that both proteins influence axon degen eration cellautonomously. Sarm1 −/− DRG neurites also seem to be protected against axon degeneration induced by NGF withdrawal 64 , although this may depend on the culture time 4 and is more transient than the protection conferred by WLD S or cytoplasmic variant NMNAT1 in the same situation 27, 42 . This might indicate that parallel SARM1dependent and independent degeneration path ways are activated after NGF withdrawal, each containing an NMNATregulated step.
The robust effect of SARM1 (or dSarm) loss of func tion after axotomy indicates a core involvement for this protein in the Wallerian degeneration pathway accord ing to our suggested criteria. Its position in this pathway seems to be upstream of calpastatin degradation and calpain activation (see below) 65 , but whether SARM1 has a role in initiation or execution remains unclear (FIG. 4) . Thus, determining its relationship to the proposed NMNATregulated step, as well as to mitochondrial and other events (below), should be revealing. In one recent report, overexpression of wildtype SARM1 did not cause axon degeneration in the absence of injury, suggesting that it requires an additional signal after injury to promote degeneration 64 . It is tempting to speculate that NMNAT2 loss or other events described below help to generate this signal. Initial structure-function studies suggest that SARM1, which is a modular protein (FIG. 2b) , dimerizes through its sterile αmotif (SAM) domains and that this promotes interaction of the associated Toll-interleukin1 receptor (TIR) signalling domains 64 . It will be important to refine these observations in order to establish whether and how SARM1 functions within axons themselves, and how its axonal role relates to its functions in promoting neuronal death after oxygenglucose deprivation 66 and cytokine regulation 67 .
Other potential modulators of initiation. Loss of SCG10 (also known as STMN2), a labile protein like NMNAT2, occurs early during the latent phase of Wallerian degen eration in DRG cultures 68 . Maintaining sufficient levels of SCG10 in injured neurites confers moderate protection against degeneration, and SCG10 depletion accelerates degeneration after injury, possibly by altering microtu bule stability 68 . However, unlike depletion of NMNAT2, depletion of SCG10 alone is not sufficient to trigger degeneration. Thus, SCG10 loss seems to be a permis sive signal for degeneration rather than causative 68 . Importantly, SCG10 turnover is JUN aminoterminal kinase (JNK)dependent, which links it to a JNK sig nalling cascade that involves dual leucine zipper kinase 69 . Interestingly, SCG10, like NMNAT2, at least partially localizes to the Golgi apparatus and Golgi derived vesicles through palmitoylation 70, 71 . It will be interesting to test for any functional interaction between these two proteins.
Other signalling cascades may also have a modifying influence on Wallerian degeneration according to our criteria. Inhibitor of nuclear factorκB kinase (IKK) and a cascade involving glycogen synthase kinase 3 (GSK3) promote axon degeneration induced by injury or non injury stresses, including NGF withdrawal, in DRG cul tures 72, 73 . However, protection following GSK3 or IKK inhibition is modest compared with the effects of WLD S (REF. 72 ), and prodegenerative manipulation of GSK3 signalling has only limited effects on uninjured neur ites 73 . As with JNK signalling (above), inhibitors of these kinases delay degeneration only when applied around the time of injury 72 , suggesting that both affect early steps in the pathway. Furthermore, the GSK3 cascade seems to act downstream of NMNAT, as various manipulations can revert WLD S mediated protection of cut axons 73 . Finally, inhibiting serine proteases delays neurite degeneration in several situations 72, 74 . TLCK, a trypsin like serine protease inhibitor, delays degeneration induced by injury, microtubule disruption or NGF withdrawal in SCG cultures 74 . Thus, like the NMNAT regulated step, activation of these proteases seems to be a common event during degeneration that is triggered by multiple different stresses. A chymotrypsinlike serine protease inhibitor, TPCK, can also delay injuryinduced neurite degeneration in DRG cultures 72 , although not in SCG cultures 74 . TPCK only delays degeneration when added around the time of injury, which again suggests that serine proteases have a role during initiation 72 . However, although there was no direct comparison, pro tection by both inhibitors seems to be much weaker than that conferred by WLD S , suggesting that serine proteases have a modifying influence based on these criteria.
The execution phase
It will be crucially important to identify the event that defines the start of the execution phase of Wallerian degeneration, as this is likely to be the point at which axons become committed to degenerate. In apopto sis, mitochondria regulate an analogous step, but in Wallerian degeneration their functions in initiation or execution have yet to be resolved (see below).
By contrast, increased intraaxonal calcium and cal pain (a calciumdependent cysteine protease) activa tion are wellestablished events in the execution phase of Wallerian degeneration 28, 65, 72, [75] [76] [77] [78] . Recent support for calpain involvement comes from a study showing that endogenous inhibition of calpain by calpastatin influences axon degeneration in primary culture and in vivo 65 . Interestingly, calpastatin degradation occurs both after injury and following NGF withdrawal in DRG neurites, suggesting that it could be a later convergence point between the Wallerian degeneration and axon pruning pathways. However, its degradation seems to be primarily calpain and caspasemediated, respectively, in these pathways 65 . It has also been confirmed that increased intra axonal calcium and calpain activation occur down stream of the proposed NMNATregulated step during Wallerian degeneration 65 . In injured DRG neurites, WLD S expression significantly delays the increase in intraaxonal calcium levels that occurs during the latent phase of Wallerian degeneration 77 , and exog enous expression of a cytoplasmic NMNAT1 mutant delays calpastatin degradation 65 . Regulation of neuronal excitability through changes in sodium and potassium channel conductance also seems to occur upstream of the changes in calcium levels 79 . The fact that the cal ciumchannel blocker nifedipine can delay Wallerian degeneration when added to DRG neurites 2 hours after injury further supports a relatively late role for calcium influx 72 . Given that a virally produced cytoplasmic NMNAT1 mutant is protective when added to primary cultures 4 hours after injury 41 , it seems likely that addi tion of nifedipine, or indeed calcium chelation, much later would also be effective.
Although pharmacological inhibition of calpains blocks cytoskeletal changes during the execution phase in injured SCG and DRG neurites, it does not prevent blebbing 28, 72, 76 . This probably reflects a failure to prevent microtubule destabilization. Crucially, calpain inhibition is significantly less protective than calcium chelation 76 . This has led to the suggestion that there are other, as yetunidentified, calciumdependent events that are involved in the execution phase 76 . Interestingly, the membrane occupation and recog nition nexus (MORN) family member Retinophilin, identified in a D. melanogaster RNAi screen for modi fiers of taxol-induced neuropathy, also seems to promote a later step during the execution phase of Wallerian degeneration, as depletion of the mouse orthologue MORN repeatcontaining protein 4 (MORN4) in DRG cultures also prevents fragmentation but not blebbing after injury 80 . Therefore, MORN4 may act downstream of intracellular calcium but on the same pathway branch as calpain activation.
Mitochondrial events: early or late?
Mitochondria have been proposed to have one or more key roles in Wallerian degeneration, but whether these roles contribute to initiation, execution or both remains undetermined. Mutations in the genes encoding mito chondrial proteins cause neurodegenerative diseases with prominent axon degeneration, including Parkinson's disease, Charcot-Marie-Tooth disease (CMT) and Friedrich's ataxia 81 . Mitochondrial malfunction lowers ATP levels, generates reactive oxygen species (ROS) and impairs calcium buffering, which leads to cellular home ostasis imbalance, mitochondrial permeability transition 
Paranodes
Axonal regions that are immediately adjacent to a node of Ranvier, surrounded by lateral loops of the myelin sheath, which form septate-like junctions with the thickened axolemma.
pore (mPTP) activation, release of proapoptotic signals and other cell death mechanisms 81 . In a nonaxotomy model, ATP depletion initiates axon degeneration and is attenuated by WLD S (REF. 56 ), consistent with an early and causative contribution to axon degeneration by mitochondria.
Early during Wallerian degeneration, mitochondria swell, fragment, accumulate at paranodes and lose their membrane potential 82 . However, whether these changes are a cause or consequence of degeneration or are gen eral markers of compromised axons remains unclear. WLD S partially colocalizes with mitochondria 8,9,83 FIG. 3) , and overexpression of the mitochondrial NMNAT isoform NMNAT3 (which is sufficient to increase total NMNAT activity at least fivefold) protects injured axons from degeneration 8 . These observations led to suggestions that NMNATs act within mitochon dria to confer axon protection. One proposal, based on observations in D. melanogaster, is that WLD S increases mitochondrial motility and calcium buffering capacity, which reduces intraaxonal calcium levels immediately after injury 84 . However, in zebrafish embryos, WLD S had only small effects on mitochondrial transport and the arrest of mitochondrial transport after injury. Furthermore, the introduction of a pink1 mutation that increases mitochondrial transport does not delay Wallerian degeneration 85 . As injury is not necessary to induce WLD S sensitive axon degeneration (see above), calcium influx cannot be the only way to activate the pathway.
Importantly, the exact sites of action of WLD S and overexpressed NMNAT3 in axons remain undetermined, and both proteins clearly also localize outside mitochon dria 8, 83 . Endogenous NMNAT3 is present at low levels in the brain despite the abundance of mitochondria 86 40 , suggesting that they act either upstream of the mitochondrial defect or on a separate pathway. This is consistent with the gradual atrophy after Milton downregulation compared to the rapid fragmen tation after dNmnat depletion 40 . The recent finding that ATP from glycolysis can drive axonal transport 89 could explain how dNmnat continues to reach axons in the absence of mitochondria and indicates that sufficient lev els of ATP can be generated in the absence of mitochon dria to support active axonal processes for some time. If the mitochondrial model is correct, these observations will need to be explained.
Whether SARM1 localizes to, and acts at, mitochon dria is also unclear. Ectopically expressed green fluores cent proteintagged SARM1 localizes to mitochondria, where it recruits JNK3 from the cytosol 66 . Based on this finding, an Nterminal mitochondrialbinding domain in SARM1 was identified 90 . However, there are conflict ing reports regarding whether this domain is required for the protein's prodegenerative function 64, 91 . A partial colocalization of endogenous SARM1 and mitochondria has been reported 64 ; although in comparison to overex pressed, tagged SARM1, the endogenous protein remains largely independent of mitochondria 4,64 . Intriguingly, SARM1 does relocalize to mitochondria in response to the encephalitis pathogen Bunyavirus, which leads to mito chondrial damage and neuronal death. It will be impor tant to determine whether similar relocalization occurs during Wallerian degeneration 92 .
Box 2 | Conservation of the NMNAT survival role
Remarkably, overexpression of slow Wallerian degeneration protein (WLD S ) confers a similarly strong axon-protective phenotype in rats, flies and zebrafish, as does ectopic expression of any mammalian nicotinamide mononucleotide adenylyltransferase (NMNAT) isoform in flies, although protection by full-length NMNAT2 is weaker 13, 14, 34, 35 . WLD S and dNmnat also protect lesioned human neurites in primary cultures 36 . Whether this evolutionary conservation of function extends to Caenorhabditis elegans is currently unclear. Overexpression of NMNAT does preserve C. elegans axons and cell bodies in the presence of constitutively open mechanosensory channels (degenerins), which cause axon degeneration and neuronal death by raising intracellular calcium levels 98 . However, preliminary findings suggest that neither WLD S nor overexpression of the two endogenous NMNATs preserves C. elegans transected axons (A. Nichols and M. Hilliard, personal communication).
Conservation of the Wallerian degeneration pathway from flies to mammals (including humans) validates Drosophila melanogaster and zebrafish as systems to study its mechanisms. This brings several crucial experimental advantages. Importantly, these organisms are already widely used to model diseases and are highly amenable to genetic manipulation. . D. melanogaster larvae, adult D. melanogaster wings and zebrafish embryos are all transparent, enabling time-lapse fluorescent imaging to be performed in vivo 35, 40 . Thus, live imaging in zebrafish of Wallerian degeneration and its consequences during development confirmed the sudden switch to axon fragmentation after a latent period 35 that was previously inferred from analysis of fixed mouse nerves 2 . Zebrafish also provide a platform for aqueous drug screening, and manipulating axon degeneration in fly or zebrafish disease models is a promising avenue for mechanistic and therapeutic studies. Finally, the generation of Wld S rats has widened the scope for studying neurodegenerative models 26,101,145 and provided a second mammalian system to test mechanistic hypotheses.
Nevertheless, there are important differences between species. C. elegans and D. melanogaster NMNATs are also required for the maintenance of neuronal cell bodies 57 , possibly reflecting the fact that there are fewer isoforms in these species. The single D. melanogaster dNmnat probably fulfils the functions of all three mammalian homologues, preserving axons and cell bodies through its enzymatic activity and/or chaperone function 58 . Mammalian evolution seems to have favoured NMNAT expression from distinct genes and tight compartmentalization of each isoform
. Thus, mammalian NMNAT2 is required for axon maintenance, but NMNAT1 may be more instrumental in neuronal cell body survival: indeed, loss-of-function mutations in Nmnat1 cause retinal neurodegeneration [136] [137] [138] [139] . Interestingly, other NAD + biosynthetic enzymes and their precursors also differ in some invertebrates 146 . These differences may be related to specialized NAD + metabolic reactions at specific locations 141 and smaller cellular dimensions. Nature Reviews | Neuroscience Mitochondria may, however, play a part in Wallerian degeneration downstream of the WLD S sensitive step. The mPTP may function during execution, as its phar macological or genetic inhibition protects degenerat ing axons 93 . An increase in ROS before degeneration, potentially originating from mitochondria or the cyto plasm, could lie upstream or downstream of mPTP activation in Wallerian degeneration [94] [95] [96] . ROS scaven gers delay Wallerian degeneration and axon pathology associated with neurodegenerative disorders 94, [97] [98] [99] , and WLD S reduces ROS accumulation 85 . Abnormalities in various mitochondrial, peroxisomal or cytosolic enzymes or in intracellular antioxidant defences can trigger ROS increases 94, 100 , and consequently the source of the ROS increase in Wallerian degeneration remains unidentified.
In summary, although mitochondria seem likely to have a role in the execution phase, and mitochon drial changes are certainly a marker of degeneration, it remains unclear whether they also help to initiate Wallerian degeneration and whether mitochondrial roles of NMNATs or SARM1 are involved.
Relationship to disease mechanisms Disease sensitivity to WLD S . It has been known for more than 10 years that WLD S prolongs axon survival in some motor neuron disease and peripheral neuropathy mod els, suggesting that there is some pathway convergence between the axon degeneration occurring in these dis eases and that following injury 33, 101 . However, as some disorders are unaffected by WLD S , it will be important to understand both the extent of the convergence and the molecular explanation for these differences 21 . Many recent studies have investigated the rela tionship between Wallerianlike mechanisms and neurodegenerative disease. Here, we have grouped the neurodegenerative models that have been studied into several categories: those in which WLD S or other NMNATs have strong effects (defined as significant axon preservation and alleviation of symptoms, where assessed), those where effects are moderate (defined as some axon preservation with only a marginal or no improvement in symptoms) and those that are insensi tive to WLD S ( 32, 95, 96 , mirroring some of these themes. Regarding disorders that are insensitive to WLD S (TABLE 1), we previously noted that these were mostly disor ders with a late onset and suggested that a 2-3 week delay in a slowly evolving disorder could be hard to detect Many events seem to be conserved in lower organisms. The various injury and non-injury stresses that are presumed to activate this putative pathway 3, 10, 27, 32, 39, 42, 56, 95, 96 are listed to the left (nerve growth factor (NGF) withdrawal additionally activates a presumed parallel pathway involving death receptor signalling and caspase activation that is required for axon pruning 43, 44 ). The pathway shown relates to events that occur in the main body of the axon and not to acute axon degeneration that occurs close to a site of physical injury. We propose that a core pathway, consisting of an initiation phase and an execution phase, receives additional input from other modifying signals. Many molecules and signals can be assigned to initiation or execution phases with some confidence (although their relative ordering remains open in many cases), but it is difficult to assign some participants, including SARM1 (which is thought to contribute to a core event), mitochondria and reactive oxygen species (ROS), to either phase based on current experimental data. As such, they are shown as provisionally influencing steps in both phases, although they probably act at only one point. There are also likely to be several gaps in the pathway as important modulators may not yet have been identified. We propose that regulation of nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) turnover and activity represents an early node in the pathway and the point at which slow Wallerian degeneration protein (WLD S ) and/or NMNAT isoform overexpression or loss of PHR1 is likely to act to delay degeneration. Endogenous NMNAT2 is predicted to inhibit the pathway in healthy axons, and rapid loss of this very labile protein could act as a trigger for pathway activation in the situations in which its delivery to axons fails. However, it remains possible that WLD S and/or NMNAT overexpression could modulate other events in the pathway downstream of NMNAT2. CRMP2, collapsin response mediator protein 2 (also known as DPYSL2); DLK, dual leucine zipper kinase; GSK3β, glycogen synthase kinase 3β; IKK, inhibitor of nuclear factor-κB kinase; JNK, JUN amino-terminal kinase; MORN4, MORN repeat-containing protein 4; MPP + , 1-methyl-4-phenylpyridinium; mPTP, mitochondrial permeability transition pore; SCG10, superior cervical ganglion 10.
model of type 2D CMT 105 and earlyonset models of spinal muscular atrophy 106, 107 , instead suggest that there are distinct pathways to axon degeneration that can be distinguished by their sensitivity to WLD S . However, it is important to note that WLD S rescue of axons can be heavily dosedependent 11 , and not all studies have tested its effects in homozygotes.
Axonal and nuclear effects of WLD S in disease. These findings have led researchers to consider how WLD S preserves axons in disease. Its effect is most easily under stood in severe axonal transport disorders in which the delivery of cargoes from cell bodies is restricted (as it is after axotomy). In particular, we have proposed that the failure to deliver NMNAT2 is a key determinant of Wallerian degeneration (see above). However, this is less likely to explain why other models, such as CMT 33,101 and the wabblerlethal mouse 108 , are WLD S sensitive. Thus, we speculate that NMNAT2 or its enzyme activity could also be depleted by other mechanisms, such as changes in tran scription, RNA processing, translation, Golgi processing, posttranslational modification or turnover.
Some interesting developments suggest that Wallerian degeneration has a wider relevance to disease than previ ously expected. It now seems that WLD S sensitive axon degeneration can be caused not only by stresses to the axon itself but also by impairment of the soma. WLD S blocks axon degeneration caused by excitotoxic damage to the retina 104 or by inhibition of protein synthesis in cell bodies in compartmentalized cultures 10 . In both cases, an additional direct effect of the stressor on proximal axons cannot be ruled out; however, as knockdown of a single gene, Nmnat2, also causes WLD S sensitive axon degenera tion 10 , it seems likely that impairment of processes within the soma, and not only within the axon itself, can initiate a pathway related to Wallerian degeneration. Surprisingly, WLD S also preserves glucose tolerance in models of type 1 and type 2 diabetes 109, 110 . Its preserva tion of pancreatic βcells after streptozotocin treatment probably involves a mechanism that is distinct from axonal protection, where WLD S clearly acts within the axon itself 9,39 37, 48 . The effect of WLD S on glucose tolerance makes it difficult to interpret whether WLD S additionally preserves axons in diabetic peripheral neuropathy. Nevertheless, when diabetes was induced in Wld S mice, neuropathy was less severe than in wildtype control mice 109 . Similarly, nuclear WLD S could sometimes preserve neuronal cell bodies in disease through a mechanism that is distinct from blocking Wallerian degeneration. In some disease models, only axons are preserved 29, 104 , or neuronal cell bodies may be protected as a result of axon survival, which ensures the continued delivery of neurotrophic factors 20, 111 . However, some studies suggest a more direct effect of WLD S in the attenuation of cell body death in ischaemic injuries 103, 112, 113 or primary culture toxicity 114 . As in models of diabetes, WLD S within neuronal nuclei could influence nuclear NAD + synthesis and thereby enzymes such as SIRT1 and PARP1 in addition to its axonal function. Moreover, NMNAT1 is known to influ ence SIRT1 and PARP1 through a direct interaction 115, 116 . It will thus be important to investigate the nuclear and axonal roles of NMNAT and WLD S , a process that may be aided by the use of NMNAT1overexpressing 54 , null and floxed mice 86 . It will be important to extend these studies to the newly identified modifiers of Wallerian degeneration (see above). The outcomes may differ according to which step in the pathway is blocked, especially for any disease mechanisms that converge downstream of the WLD S modifiable step. Moreover, whereas WLD S may addition ally prevent disruption of nuclear NAD + metabolism (see above), other modifiers of an axonspecific pathway may not. In this regard, it is interesting to note that SARM1 has already been reported to modify ischaemiainduced damage 66 and its genomic locus is associated with ALS
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. In summary, the homogeneity and predictability of axon degeneration after injury (FIG. 1c) has led to sub stantial advances in understanding this mechanism. This in turn sheds light on the more difficult challenge of understanding axon degeneration in disease, where onset is more heterogeneous, dispersed and multifacto rial (FIG. 1a,b) 27, 29 , and retinal ganglion cells continue to die in some glaucoma and excitotoxic retinal injury models 26, 119 . Against this background, the identification of the innate immunity signalling molecule SARM1 (REFS 4, 120) as a regulator of Wallerian degeneration was surprising. SARM1 is one of five mammalian TLR adap tors. It seems not to induce nuclear factorκB signalling like other TLR adaptors 120 but does alter susceptibility to several specific viruses 92, 121, 122 . The most intensively studied role of innate immunity is the recognition of pathogens and induction of an inflammatory response to remove them or of cell death to minimize their spread. However, in addition to pathogens, some host molecules also signal through TLRs to induce cell death: for exam ple, the microRNA let7 interacts with TLR7, providing a possible mechanism of cell damage signalling 123 . Thus, one could speculate that SARM1 is similarly activated by an intraaxonal injury signal. The nature of such a signal and its putative receptor remain unclear, but as SARM1 requires its TIRsignalling domain to induce axon degeneration, a TLR signalling mechanism seems to be the most likely candidate 64 . SARM1 also influences virally induced death in cor tical neuron primary cultures 92 . An important question is whether Wallerian degeneration and some types of cell death are initiated differently but share a common, downstream mechanism, perhaps with SARM1 lying beyond the convergence point.
Finally, there are emerging links to neuronal devel opment. First, NMNAT2 is required for axons to grow beyond a threshold length as well as for survival of established axons 11, 12 . Intriguingly, NMNAT2 levels also increase proximally to an axon lesion, where NMNAT2 could function in regrowth 10 . Second, in primary hip pocampal neurons, Sarm1 knockdown strongly reduces dendritic branching, alters spine morphology and reduces axon growth 124 , and SARM1 depletion in vivo reduces brain weight and dendritic branching 124 . Third, a lossoffunction mutation in highwire results in synaptic overgrowth in D. melanogaster 125 . However, a different Highwire ubiquitylation substrate, Wallenda, mediates this developmental phenotype as well as an increase in axon sprouting after injury and a modest effect on axon degeneration 15 . Thus, there may be some similarities between regulation of axon and dendrite growth and Wallerian degeneration, but some effects may reflect multiple functions for these proteins.
Evolution of Wallerian degeneration
Recent developments also demand that we rethink how Wallerian degeneration evolved. As rapid Wallerian degeneration is a necessary step towards axon regenera tion in peripheral nerves, it is often assumed that this is its evolutionary advantage 126 . However, it is hard to see this as a major driver of evolution, as freeliving animals are unlikely to survive long enough after nerve injury for regeneration. Furthermore, it now seems that Wallerian degeneration evolved in a common ancestor of mam mals and flies so its advantage must be considered in this context. As most invertebrates lack adaptive immunity, innate immunity confers a powerful survival advantage. Many viruses spread around the nervous system using axonal transport 127, 128 , so an intriguing possibility is that rapid axon degeneration originally arose as a mecha nism to limit this spread and was only later adopted as a response to injury.
Although difficult to prove, there are interesting impli cations for neuropathology in humans and other mam mals. West Nile virus requires intact peripheral nerves to enter the CNS 129 , and removal of SARM1 increases its replication in the brainstem 122 , consistent with a role for intact axons in virus replication. Thus, axon degeneration could limit the spread of this virus, a notion proposed pre viously for Theiler's murine encephalomyelitis virus 130 . SARM1 expression also responds to viral infections: it increases during an infection with La Crosse virus, in which it may contribute to neuronal death in paediatric viral encephalitis 92 ; and it decreases after infection with porcine reproductive and respiratory syndrome virus 121 .
Other viral disorders are associated with axon damage, notably human immunodeficiency virus, which causes distal sensory neuropathy in the periphery and axonal transport disruption in the CNS 131, 132 . Virusinduced axon degeneration could contribute to some cases of multiple sclerosis, potentially underlying the socalled 'insideout' model, which proposes that demyelination and the autoimmune response are secondary events 133 . The potential roles of major histocompatibility complex expression in ALS and chemokine secretion in CMT could also indicate an innate immune role in axon sur vival 134, 135 . It will be particularly important to determine whether SARM1, and degenerative pathways related to Wallerian degeneration, are required for many of these pathologies.
Conclusions and perspective
Until recently, expression of WLD S or related NMNATs was the only known way to preserve severed axons for weeks in vivo and days in primary culture. In paral lel with an improved understanding of their actions, several additional modulators with an equally robust effect have now emerged. We propose that they lie on the same putative core pathway, whereas proteins influ encing Wallerian degeneration less strongly modify this pathway. Alternatively, there could be other equally important but still unknown pathways in which some of these factors act. Morphologically, Wallerian degen eration involves a latent phase followed by abrupt frag mentation, probably with a commitment point prior to fragmentation. The updated list of disease models influ enced by WLD S and NMNATs (TABLE 1) shows clusters of some disease types but as yet no underlying principle. The additional functions of recently identified modifiers SARM1 and PHR1 (and their D. melanogaster homo logues) in innate immunity and synapse growth suggest possible links between the Wallerian degeneration mechanism and other important areas of neuroscience. This is an exciting time for the field as this progress opens many new questions. Foremost among them is whether, as we propose, SARM1 and PHR1 lie on the same pathway as NMNAT and, if so, which steps are upstream and which downstream. Ongoing genetic screens in D. melanogaster and functional studies of existing modulators should reveal additional steps in the putative pathway. The involvement of mitochondria needs further clarification and the molecular identity of the commitment point is critically important. Any suc cessful therapy will need to target a step preceding this point. It is important to determine what activates the prodegenerative action of SARM1 and whether this relates to its roles in innate immunity and cell death.
From a therapeutic viewpoint, the key questions are how, and in which disorders, to target the emerg ing pathway. Temporary periods of axon stress, such as chemotherapyinduced peripheral neuropathy, multiple sclerosis relapses or stroke, would seem to be better initial goals than chronic disease, as permanently compromised axons are protected only for limited periods. Inhibition of NAMPT, JNK, GSK3β and other proteins can preserve injured axons in primary culture, albeit more modestly than genetic mutations, so it is essential to understand their modes of action and to pursue these studies in vivo. In parallel with attempts to mimic SARM1 and PHR1 loss of function pharmacologically, genetic studies to test which disease models they influence are needed. Unlike WLD S , the SARM1 and PHR1null phenotypes do not require the delivery of a protein into axons, suggesting that they may provide a more longlasting protection in transport disorders. Actions at different points in the pathway could lead to different therapeutic profiles. For example, if disease pathways converge, blocking a step downstream of the convergence but before the commit ment to degenerate should have a wider protective effect.
Finally, it will be important to translate this knowledge into strategies for targeting human disease, especially as WLD S preserves human axons 36 and NMNAT1 deficiency causes neurodegeneration in humans [136] [137] [138] [139] . The ability of SARM1 and WLD S to influence cell body survival in some circumstances suggests that it is feasible that com binatorial therapies could protect both cellular compart ments. The genetic association of axonal disorders, or relative resistance to them, with haplotypes of NMNAT1, NMNAT2 or NMNAT3, SARM1, PHR1 and other modu lators is an important area for human studies, as is the identification of biomarkers that provide mechanistic insight and diagnostic capability.
